MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ
3.040
-0.330
-9.79%
Closed 18:57 04/24 EDT
OPEN
3.370
PREV CLOSE
3.370
HIGH
3.420
LOW
3.030
VOLUME
2.11M
TURNOVER
0
52 WEEK HIGH
6.89
52 WEEK LOW
2.230
MARKET CAP
514.04M
P/E (TTM)
-1.4578
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ALLO last week (0415-0419)?
Weekly Report · 3d ago
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
Cathie Wood's fund ARK Invest invests in companies she expects to be the leaders of disruptive innovation. The fund is down 15% this year. Wood is a fan of investing in the companies of tomorrow. Her fund invests in the cutting-edge technologies of the day.
Benzinga · 6d ago
Weekly Report: what happened at ALLO last week (0408-0412)?
Weekly Report · 04/15 09:09
3 Meme Stocks to Sell and Replace With Meme Coins
Three meme stocks to sell include Rivian Automotive (RIVN), Tupperware Brands (TUP) and Allogene Therapeutics (ALLO) Social media has overshadowed the investing fundamentals, spotlighting meme stocks as prime candidates to sell. All three stocks are down 92% since November 2021.
Investorplace · 04/11 18:45
How Allogene (ALLO) Stock Stands Out in a Strong Industry
NASDAQ · 04/08 12:46
Weekly Report: what happened at ALLO last week (0401-0405)?
Weekly Report · 04/08 09:10
Showcasing Seeking Alpha's March 2024 New Analysts
Home Stock Ideas Quick Picks & Lists Showcasing Seeking Alpha's March 2024 New Analysts. There were 24 new analysts in March 2024. Gold, Bitcoin, a Bitcoin proxy pair trade, preferred shares, and a SOTP thesis are all covered. This month, we welcome the 24 analysts who published articles in March.
Seeking Alpha · 04/05 15:30
Weekly Report: what happened at ALLO last week (0325-0329)?
Weekly Report · 04/01 09:10
More
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.

Webull offers Allogene Therapeutics Inc stock information, including NASDAQ: ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.